Cargando…

Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients

BACKGROUNDS: Various studies have reported that the neutrophil-to-lymphocyte ratio in the serum (sNLR) may serve as a cost-effective and useful prognostic factor in patients with various cancer types. However, no study has reported the prognostic impact of the NLR in malignant pleural effusion (MPE)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yong Seok, Nam, Hae-Seong, Lim, Jun Hyeok, Kim, Jung Soo, Moon, Yeonsook, Cho, Jae Hwa, Ryu, Jeong-Seon, Kwak, Seung Min, Lee, Hong Lyeol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567470/
https://www.ncbi.nlm.nih.gov/pubmed/28830378
http://dx.doi.org/10.1186/s12885-017-3550-8
_version_ 1783258738960891904
author Lee, Yong Seok
Nam, Hae-Seong
Lim, Jun Hyeok
Kim, Jung Soo
Moon, Yeonsook
Cho, Jae Hwa
Ryu, Jeong-Seon
Kwak, Seung Min
Lee, Hong Lyeol
author_facet Lee, Yong Seok
Nam, Hae-Seong
Lim, Jun Hyeok
Kim, Jung Soo
Moon, Yeonsook
Cho, Jae Hwa
Ryu, Jeong-Seon
Kwak, Seung Min
Lee, Hong Lyeol
author_sort Lee, Yong Seok
collection PubMed
description BACKGROUNDS: Various studies have reported that the neutrophil-to-lymphocyte ratio in the serum (sNLR) may serve as a cost-effective and useful prognostic factor in patients with various cancer types. However, no study has reported the prognostic impact of the NLR in malignant pleural effusion (MPE). To address this gap, we investigated the clinical impact of NLR as a prognostic factor in MPE (mNLR) and a new scoring system that use NLRs in the serum and MPE (smNLR score) in lung cancer patients. METHODS: We retrospectively reviewed all of the patients who were diagnosed with lung cancer and who presented with pleural effusion. To maintain the quality of the study, only patients with malignant cells in the pleural fluid or tissue were included. The patients were classified into three smNLR score groups, and clinical variables were investigated for their correlation with survival. RESULTS: In all, 158 patients were classified into three smNLR score groups as follows: 84 (53.2%) had a score of 0, 58 (36.7%) had a score of 1, and 16 (10.1%) had a score of 2. In a univariate analysis, high sNLR, mNLR, and increments of the smNLR score were associated with shorter overall survival (p < 0.001, p = 0.004, and p < 0.001, respectively); moreover, age, Eastern Cooperative Oncology Group performance status (ECOG PS), histology, M stage, hemoglobin level, albumin level, and calcium level were significant prognostic factors. A multivariable analysis confirmed that ECOG PS (p < 0.001), histology (p = 0.001), and smNLR score (p < 0.012) were independent predictors of overall survival. CONCLUSIONS: The new smNLR score is a useful and cost-effective prognostic factor in lung cancer patients with MPE. Although further studies are required to generalize our results, this information will benefit clinicians and patients in determining the most appropriate therapy for patients with MPE. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3550-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5567470
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55674702017-08-29 Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients Lee, Yong Seok Nam, Hae-Seong Lim, Jun Hyeok Kim, Jung Soo Moon, Yeonsook Cho, Jae Hwa Ryu, Jeong-Seon Kwak, Seung Min Lee, Hong Lyeol BMC Cancer Research Article BACKGROUNDS: Various studies have reported that the neutrophil-to-lymphocyte ratio in the serum (sNLR) may serve as a cost-effective and useful prognostic factor in patients with various cancer types. However, no study has reported the prognostic impact of the NLR in malignant pleural effusion (MPE). To address this gap, we investigated the clinical impact of NLR as a prognostic factor in MPE (mNLR) and a new scoring system that use NLRs in the serum and MPE (smNLR score) in lung cancer patients. METHODS: We retrospectively reviewed all of the patients who were diagnosed with lung cancer and who presented with pleural effusion. To maintain the quality of the study, only patients with malignant cells in the pleural fluid or tissue were included. The patients were classified into three smNLR score groups, and clinical variables were investigated for their correlation with survival. RESULTS: In all, 158 patients were classified into three smNLR score groups as follows: 84 (53.2%) had a score of 0, 58 (36.7%) had a score of 1, and 16 (10.1%) had a score of 2. In a univariate analysis, high sNLR, mNLR, and increments of the smNLR score were associated with shorter overall survival (p < 0.001, p = 0.004, and p < 0.001, respectively); moreover, age, Eastern Cooperative Oncology Group performance status (ECOG PS), histology, M stage, hemoglobin level, albumin level, and calcium level were significant prognostic factors. A multivariable analysis confirmed that ECOG PS (p < 0.001), histology (p = 0.001), and smNLR score (p < 0.012) were independent predictors of overall survival. CONCLUSIONS: The new smNLR score is a useful and cost-effective prognostic factor in lung cancer patients with MPE. Although further studies are required to generalize our results, this information will benefit clinicians and patients in determining the most appropriate therapy for patients with MPE. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3550-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-08-22 /pmc/articles/PMC5567470/ /pubmed/28830378 http://dx.doi.org/10.1186/s12885-017-3550-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Lee, Yong Seok
Nam, Hae-Seong
Lim, Jun Hyeok
Kim, Jung Soo
Moon, Yeonsook
Cho, Jae Hwa
Ryu, Jeong-Seon
Kwak, Seung Min
Lee, Hong Lyeol
Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients
title Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients
title_full Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients
title_fullStr Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients
title_full_unstemmed Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients
title_short Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients
title_sort prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567470/
https://www.ncbi.nlm.nih.gov/pubmed/28830378
http://dx.doi.org/10.1186/s12885-017-3550-8
work_keys_str_mv AT leeyongseok prognosticimpactofanewscoreusingneutrophiltolymphocyteratiosintheserumandmalignantpleuraleffusioninlungcancerpatients
AT namhaeseong prognosticimpactofanewscoreusingneutrophiltolymphocyteratiosintheserumandmalignantpleuraleffusioninlungcancerpatients
AT limjunhyeok prognosticimpactofanewscoreusingneutrophiltolymphocyteratiosintheserumandmalignantpleuraleffusioninlungcancerpatients
AT kimjungsoo prognosticimpactofanewscoreusingneutrophiltolymphocyteratiosintheserumandmalignantpleuraleffusioninlungcancerpatients
AT moonyeonsook prognosticimpactofanewscoreusingneutrophiltolymphocyteratiosintheserumandmalignantpleuraleffusioninlungcancerpatients
AT chojaehwa prognosticimpactofanewscoreusingneutrophiltolymphocyteratiosintheserumandmalignantpleuraleffusioninlungcancerpatients
AT ryujeongseon prognosticimpactofanewscoreusingneutrophiltolymphocyteratiosintheserumandmalignantpleuraleffusioninlungcancerpatients
AT kwakseungmin prognosticimpactofanewscoreusingneutrophiltolymphocyteratiosintheserumandmalignantpleuraleffusioninlungcancerpatients
AT leehonglyeol prognosticimpactofanewscoreusingneutrophiltolymphocyteratiosintheserumandmalignantpleuraleffusioninlungcancerpatients